Quantcast

Latest Quinazolines Stories

2010-12-09 17:20:06

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer.

2010-12-09 07:45:00

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs.

2010-12-09 07:45:00

WALTHAM, Mass., Dec. 9, 2010 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC).

2010-12-01 13:15:22

A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.

2010-11-20 00:00:47

Results from Phase II biomarker analysis of erlotinib in combination with sorafenib presented at Molecular Targets in Cancer Therapeutic meeting in Berlin, Germany. Broomfield, CO (Vocus) November 19, 2010 Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in...

2010-11-17 13:41:47

Scientists believe they may have found a new target for treating triple negative breast cancer – one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

2010-11-10 12:17:00

BROOMFIELD, Colo., Nov. 10, 2010 /PRNewswire/ -- Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, lead by existing investors.

2010-11-10 06:00:00

BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc.

2010-10-12 18:07:56

A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related